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ABSTRACT
NF-iB is involved in immune responses, inflamma-
tion, oncogenesis, cell proliferation and apoptosis.
Even though NF-iB can be activated by DNA
damage via Ataxia telangiectasia-mutated (ATM)
signalling, little was known about an involvement in
DNA repair. In this work, we dissected distinct DNA
double-strand break (DSB) repair mechanisms re-
vealing a stimulatory role of NF-iB in homologous
recombination (HR). This effect was independent of
chromatin context, cell cycle distribution or cross-
talk with p53. It was not mediated by the transcrip-
tional NF-iB targets Bcl2, BAX or Ku70, known for
their dual roles in apoptosis and DSB repair. A con-
tribution by Bcl-xL was abrogated when caspases
were inhibited. Notably, HR induction by NF-iB
required the targets ATM and BRCA2. Additionally,
we provide evidence that NF-iB interacts with CtIP–
BRCA1 complexes and promotes BRCA1 stabiliza-
tion, and thereby contributes to HR induction.
Immunofluorescence analysis revealed accelerated
formation of replication protein A (RPA) and Rad51
foci upon NF-iB activation indicating HR stimulation
through DSB resection by the interacting CtIP–
BRCA1 complex and Rad51 filament formation.
Taken together, these results define multiple NF-iB-
dependent mechanisms regulating HR induction, and
thereby providing a novel intriguing explanation for
both NF-kB-mediated resistance to chemo- and
radiotherapies as well as for the sensitization by
pharmaceutical intervention of NF-kB activation.
INTRODUCTION
The transcription factor family NF-iB regulates the ex-
pression of more than 150 genes and encompasses ﬁve
members, namely RelA (p65), RelB, c-Rel, p50/p105
(NF-iB1) and p52/p100 (NF-iB2), which form various
homo- and hetero-dimers (1). In the majority of cell
types, these dimers are retained in the cytoplasm due to
association with the inhibitory IiB-family proteins such as
IiBa,I iBb and IiBe. Different stimuli lead to NF-iB
activation and almost all of them funnel in the activation
of IiB-kinase (IKK) complex. The IKK complex consists
of IKKa and IKKb, which form the catalytic subunit, and
the regulatory subunit IKKg (NEMO). In the canonical
pathway, activation of the IKK complex results in phos-
phorylation of IiBa on Ser32 and Ser36, which marks it
for ubiquitination and proteasomal 26S degradation. It
has been well-established that cytotoxic drugs and
ionizing radiation activate NF-iB (1,2), which results in
the induction of anti-apoptotic genes contributing to
chemo- and radio-resistance of tumour cells. The
pathway triggered by DNA damage merges with the
canonical NF-iB pathway involving p65/p50 hetero-
dimers and IiBa. Recent evidence has shown that the
DNA damage sensor poly-(ADP-ribose)-polymerase-1
(PARP1) assembles Ataxia telangiectasia mutated
(ATM) and SUMO-1 ligase PIASy resulting in phosphor-
ylation and SUMOylation of IKKg and thereby IKK
activation (3).
Double-strand breaks (DSBs) in mammalian cells can
be repaired by non-homologous end joining (NHEJ),
single-strand annealing (SSA) and homologous recombin-
ation (HR) (4). NHEJ occurs throughout the cell cycle,
while HR is limited to the S/G2-phase of the cell cycle. So
far, only little is known about the contribution of NF-kB
in DNA repair. Studies with murine ﬁbroblasts showed
that loss of p65 compromises DNA repair and genome
stability during cellular senescence (5). Different observa-
tions were made in glioblastoma cells, where NF-iB
promoted accumulation of ssDNA breaks and apoptosis
(6). One report described that TNFa induces the inter-
action between p65 and the HR protein BRCA1 leading
to enhanced NF-iB transcriptional activity (7). According
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cient NF-iB activation after camptothecin treatment (8).
In the present work, we deﬁne the role of NF-iB in DSB
repair, its downstream targets and the mechanism of
action in different cell types.
MATERIALS AND METHODS
Cell lines and cultivation
K562(/30) cells originating from the human myeloid leu-
kaemia cell line K562, carrying stably integrated
-EGFP/30EGFP repair substrate (9) and parental K562
cells were cultivated in RPMI 1640 (PAA Laboratories,
Pasching, Germany) supplemented with 10% FCS (PAA
Laboratories) and 1% L-glutamine (Biochrom, Berlin,
Germany). U87MG glioblastoma cell derivatives, stably
expressing IiBa-SR (U87MG-SR), were generated as de-
scribed in Karl et al. (6). HeLa knockdown cells (Control,
Mre11, ATM, BRCA2, BRCA1) HeLa SilenciX were
purchased from tebu-bio and maintained in DMEM
High Glucose-Medium (PAA Laboratories), 10% FCS
(PAA Laboratories) and 125mg/ml Hygromycin B
(Roche, Mannheim, Germany). The human primary
osteogenic sarcoma cell line SaOS was cultivated in
McCoys (Invitrogene Gibco, Karlsruhe, Germany) with
10% FCS (PAA Laboratories) and 1% L-glutamine.
Human glioblastoma cells U87MG were maintained in
DMEM High Glucose-Medium (PAA Laboratories),
10% FCS (PAA Laboratories) and 1% L -glutamine.
Transfections, DSB repair, drug treatment and gene
silencing
DSB repair was examined by the use of the EGFP-based
test system as described in Akyu ¨ z et al. (9). To determine
DSB repair frequencies, K562(/30) cells were transfected
via electroporation (Bio-Rad Laboratories, Hercules, CA,
USA) with 10mg pCMV-I-SceI, 10mg pBS/wtEGFP
plasmid (see below), 40mg of pcDNA3.0-IiBa-SR expres-
sion plasmid/empty vector and/or 40mg pcDNA3.0-p65
expression plasmid/empty vector. Cells were split
into two aliquots and cultivated for 24h when 10ng/ml
TNFa (Active Bioscience, Hamburg, Germany), 50mM
etoposide (Sigma-Aldrich, Mu ¨ nchen, Germany) or 300nM
camptothecin (Sigma-Aldrich) were added. Transfected
cells were cultivated for another 24 or 48h when they
were analysed ﬂow cytometrically for EGFP positivity
(Supplementary Figure S3). When studying different
DSB repair pathways, the following repair substrates
were used: EJ-EGFP, HR-EGFP/50EGFP and 50EGFP/
HR-EGFP to evaluate NHEJ, HR and SSA, respectively
(Figure 4A). K562 cells were electroporated with 10mg
pCMV-I-SceI, 10mg pBS/wtEGFP plasmid, 10mgo f
repair substrate, 30mg of pcDNA3.0-IiBa-SR expression
plasmid/empty vector and/or 30mg of pcDNA3.0-p65 ex-
pression plasmid/empty vector. HeLa cells were trans-
fected with FuGENE reagent (Roche) and a mixture of
4mg DNA consisting of pCMV-I-SceI, pBS/wtEGFP
plasmid, repair substrate to assess HR (HR-EGFP/
50EGFP) and pcDNA3.0-p65 expression plasmid/empty
vector. To down-regulate expression of speciﬁc proteins
during repair measurements in K562(/30) and K562
cells, cells were transfected with a mixture of two or
three different knockdown plasmids generating target-
speciﬁc shRNAs. To silence Bcl2, 40mg of pRSBcl2-4
(50-GCGACTTCGCCGAGATGTCCAGCCAGCTG-30)
and pRSBcl2-6 (50-TGATTTCTCCTGGCTGTCTCTGA
AGACTC-30) or pRS control plasmid were added to the
DNA mixture; 30mg of pRSBcl-xL-4 (50-TTAGTGATGT
GGAAGAGAACAGGACTGAG-30), pRSBcl-xL-6 (50-C
TCACTCTTCAGTCGGAAATGACCAGACA-30) and
pRSBcl-xL-7 (50-CACCACATCCTCCGTCCAGCCGC
CATTGC-30) were used to knockdown Bcl-xL; 40mgo f
pRSBAX-3 (50-GACGAACTGGACAGTAACATGGA
GCTGCA-30), pRSBAX-5 (50-TTTCTACTTTGCCAGC
AAACTGGTGCTCA-30) and pRSBAX-6 (50-GTGCCT
CAGGATGCGTCCACCAAGAAGCT-30) were used
to down-regulate BAX expression; 40mg of pRSCtIP-6
(50-TCGGTTAAGAGCAGGCTTATGTGATCGCT-30)
and pRSCtIP-8 (50-GGTGAACAGAATAGGACTGAG
TACGGTAA-30) were used to silence CtIP; 40mgo f
pRSBRCA1-4 (50-AGGACCTGCGAAATCCAGAACA
AAGCACA-30) and pRSBRCA1-6 (50-AAATGCCAGT
CAGGCACAGCAGAAACCTA-30) were utilized to
knockdown BRCA1. All above-mentioned knockdown
plasmids were purchased from Origene, Rockville, MD,
USA, and speciﬁc targeted sequences are as indicated. To
down-regulate expression of Ku70, knockdown plasmid as
described in Uhl et al. (10) was applied.
Following cultivation for 48 or 72h [K562(/30), K562]
or 24h (HeLa), 50000–200000 living cells were examined
to determine EGFP-positive and EGFP-negative cells by
the diagonal gating method in the FL1/FL2 dot plot
(FACS Calibur FACScan, BD Biosciences, Heidelberg,
Germany) (9). Each transfected sample was accompanied
by a sample transfected with the same DNA mixture
except that the ﬁller plasmid pBS was substituted by
wtEGFP expression plasmid to determine the transfection
efﬁciency. Each quantiﬁcation of green ﬂuorescent cells in
repair assays (with pBS) was normalized by use of the indi-
vidually determined transfection efﬁciency (with wtEGFP
plasmid) to calculate the DSB repair frequency (absolute
value). In this way, we corrected for potential differences
in transfection, transcription, translation, proliferation
and lethality. The statistical signiﬁcance of differences
was determined using Wilcoxon-matched pairs test, two
tailed (P<0.05), with the software GraphPad Prism
version 5.01. In Figures and Supplementary Figures
graphically presenting data, all statistically signiﬁcant
changes, i.e. after comparing each single mean value with
each other in the graph, are indicated by brackets and
1–3 stars (*P<0.05; **P<0.01; ***P<0.001).
Cell cycle, apoptosis and survival
Cell cycle and apoptosis data were obtained by FACS
analysis on ethanol/acetone ﬁxed and propidium iodide
stained cells (10), which were processed under the condi-
tions of the DSB repair assay.
For survival analysis K562(/30) cells were transfected
with p65 expression/empty control vector as for DSB
repair measurements. Twenty-four hours later the cells
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well and treated with 16–1000mM of the PARP inhibitor
IQD (Calbiochem). Cells were cultivated for 8 days during
which fresh IQD was applied every 3 days, and MTT
assay was performed.
Western blotting and antibodies
Cellular lysates were prepared by incubating cell samples
in lysis buffer (50mM Tris, pH 7.4; 150mM NaCl;
2mM EGTA; 2mM EDTA; 25mM NaF; 25mM
b-glycerophosphate; 0.1mM NaV; proteinase inhibitor,
Roche). To examine the phosphorylation status of pro-
teins, phosphatase inhibitor was added into the lysis buffer
(PhosSTOP Phosphatase Inhibitor Cocktail Tablets,
Roche). Protein concentrations were determined by the
BCA
TM Protein Assay Kit (Thermo Scientiﬁc, Rockford,
IL, USA) and 60–80mg of protein were loaded onto
8–15% SDS–PAGE gels. Electrophoresed protein
samples were blotted onto Hybond
TM-C Extra or
Hybond
TM-P (GE Healthcare, Mu ¨ nchen, Germany) mem-
branes and detected by use of the following antibodies:
ATM mAb 5C2 (Abcam, Cambridge, UK), BAX mAb
2D2 (Calbiochem, Darmstadt, Germany), Bcl2 mAb 100
(Santa Cruz, Heidelberg, Germany), Bcl-xL mAb 2H12
(Pharmigen, BD Biosciences, Heidelberg, Germany),
BRCA1 mAb Ab-1 Clone MS110 (Calbiochem), BRCA2
mAb Ab-1 Clone 2B (Calbiochem), CtIP anti goat T-16
(Santa Cruz), DNA-PKcs Cocktail Ab-4, Clone 18-12,
25-4, 42 psc (Neomarkers), IiBa rabbit serum C-21
(Santa Cruz), phospho-IiBa mAb 5A5 (Cell Signaling,
Boston, MA, USA), Ku70 mAb S5C11 (Abcam), Mre11
rabbit serum (Novus Biologicals, Littleton, CO, USA),
p65 rabbit C-20 (Santa Cruz), GAPDH mouse monoclo-
nal antibody (Abcam) and tubulin mAb DM1A (Abcam).
Western blot signals were visualised by Super Signal
West Pico Chemiluminescent Substrate or Super Signal
West Dura Extended Duration Substrate (Thermo
Scientiﬁc). Densitometric quantiﬁcation of band inten-
sities on autoradiographs was performed using a
ChemImager 5500 and corresponding software enabling
background subtraction (Alpha Imunotech Corporation,
San Leonardo, CA, USA). Values of band intensities for
the protein of interest were corrected with the values
obtained for the corresponding loading control each.
Relative differences in band intensities mentioned in the
text were calculated from the band intensities stemming
from the representative western blot depicted in the cor-
responding ﬁgure each (from at least two western blots per
protein). Please note that for quantiﬁcation autoradio-
graphs were scanned separately, which may explain differ-
ent sensitivities in band detection regarding low protein
levels.
Immunoﬂuorescence analysis
SaOS cells were cultured on cover slips and exposed to
bleomycin (7.5–100mU, Sigma-Aldrich) alone or in com-
bination with TNFa (10ng/ml). For p65 expression, SaOs
cells were transfected by nucleofection according to the
amaxa protocol (Lonza, Cologne, Germany) with a
mixture of 5mg pBS and pcDNA3.0-p65 expression
plasmid/empty vector DNA. After 24h, cells were treated
with 30mU bleomycin. At the indicated times cells were
ﬁxed with 3.7% formaldehyde and permeabilized with
0.5% triton. To quantify replication protein A (RPA)
or Rad51 foci cells were additionally pre-extracted with
0.2–0.5% triton solution. Cover slips with ﬁxed cells
were washed with PBS, 0.05% tween and blocked with
7% goat serum and immunostained with primary anti-
bodies in 7% goat serum PBS solution. Subsequently,
the cells were incubated with secondary antibody,
stained with DAPI and the cover slips were mounted in
a mixture of Mowiol and Dapco (3:1). Fluorescence
micrographs were collected at RT on an Olympus BX51
epiﬂuorescence microscope equipped with UPLAN FI ob-
jective lenses (40 /0.75 and 100 /1.3 from Olympus)
ﬁtted with a thermoelectronically cooled, charge-coupled
device camera (model colour view 12 from Soft Imaging
System). Grayscale source images were captured separate-
ly after ﬂuorescence excitation with the following
Olympus ﬁlter module: U-MNG2 (Alexa Fluor 555), or
U-MNU2 (DAPI). AnalySIS software including the mFIP
module (version Auto 3.2, Soft Imaging System) was used
for image acquisition, overlays and analysis. For the auto-
mated identiﬁcation and visualization of nuclear foci
with high ﬂuorescence intensity versus diffuse staining, a
colour intensity threshold was set and maintained for
all images. Antibodies used for immunoﬂuorescence
analysis were: 53BP1 rabbit (Novus), RPA mAb clone
34-19 (Calbiochem), Rad51 rabbit H-92 (sc-8349, Santa
Cruz), Alexa Fluor 555 conjugated secondary antibodies
(Invitrogen).
RESULTS
TNFa activates DSB repair
In order to analyse the potential role of NF-iB in DSB
repair, we used an EGFP-based model system, where
DSBs are introduced via meganuclease I-SceI-targeted
cleavage in mutated EGFP variants (9). K562(/30) cells,
which carry a stably integrated repair substrate supporting
homologous DSB repair via HR and SSA (Figure 1A),
were co-transfected with I-SceI- and IiBa-SR expression
or control vectors. Expression of IiBa-SR is a well-known
tool to block NF-kB-activation by conferring resistance to
TNF-induced degradation (Figure 1F), (6). Cells were
exposed to the NF-iB-activating stimulus TNFa 24h
post-transfection and FACS-analysed for EGFP positivity
after another incubation period of 24h. The results re-
vealed 3.1-fold increased DSB repair in cells treated with
TNFa (P=0.0039). In the cells, additionally, expressing
IiBa-SR both basal (3.5-fold) and TNFa-induced
(2.7-fold) DSB repair was down-regulated (P<0.01;
Figure 1B). Since a TNFa-mediated induction of DSB
repair could still be detected in cells expressing IiBa-SR,
a NF-kB-independent effect of TNFa action is conceiv-
able. However, we cannot exclude incomplete blockage
of NF-kB activation by IiBa-SR (Supplementary
Figure S1C).
To prove that the NF-iB-signalling pathway is func-
tional under these conditions, we analysed the
Nucleic AcidsResearch, 2012, Vol.40,No. 1 183phosphorylation status of endogenous IiBa, performed
NF-kB DNA-binding studies and NF-kB-dependent re-
porter gene assays (Supplementary Figure S1). TNFa
exposure led to marked IiBa phosphorylation, strong
DNA binding as well as 4-fold (P=0.0039) increased
NF-iB-dependent GFP transcription. IiBa-SR expression
compromised DNA binding and GFP expression in
TNFa-treated samples. Since TNFa also activates caspase
8 and the pro-apoptotic JNK pathway (1), which might
lead to degradation of repair proteins, the role of apop-
tosis was addressed in this scenario. For this purpose, cells
were pre-treated with the broad range caspase inhibitor
z(VAD)-fmk. Under these conditions, TNFa-induced
DSB repair was found to be unchanged (Figure 1C and
B). Furthermore, the suppressive effect of IiBa-SR on
DSB repair ( /+TNFa) matched the effect in cells
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Figure 1. Effect of TNFa on DSB repair. (A) Design of substrate -EGFP/30EGFP to monitor conservative and non-conservative homologous DSB
repair. The ﬂuorescence-based DSB repair assay monitors reconstitution of wild-type (wt) EGFP after I-SceI meganuclease-mediated cleavage of the
mutated EGFP gene D-EGFP, which is under the control of a CMV promoter (black box and kinked arrow), via determination of the fraction of
green ﬂuorescent cells within the total population (9). Each measurement was accompanied by the analysis of split samples after transfection of the
cells with the same DNA mixture as in DSB repair measurements, but replacing ﬁller pBS plasmid by wtEGFP-expressing plasmid of the DSB repair
substrate design. Fractions of green ﬂuorescent cells obtained were thus normalized with the individual transfection efﬁciency for each sample to give
DSB repair frequencies, thereby excluding differences in transfection, transcription, translation, proliferation and lethality. Substrate -EGFP/
30EGFP enables the analysis of conservative HR plus non-conservative SSA repair processes. Mutated EGFP genes: grey boxes; spacer sequence
(hygromycin resistance gene cassette): white box; I-SceI site: triangle; deleted EGFP sequence: cross. (B) Inﬂuence of TNFa on DSB repair was
analysed in K562(/30) cells carrying stably integrated homologous DSB repair substrate -EGFP/30EGFP. Cells were electroporated with
pCMV-I-SceI for targeted substrate cleavage together with expression plasmid for the NF-iB antagonist IiBa-SR (pcDNA3.0-IiBa-SR) or with
pcDNA3.0 in controls. After 24h cells were treated with 10ng/ml TNFa and cultivated for another 24h, when DSB repair frequencies were
determined. DSB repair frequencies in H2O-treated controls were deﬁned as 100% each (absolute mean value 1 10
 3). Mean values and SEMs
from n=9 (**P<0.01). (C) In parallel, cells were treated with 25mM caspase inhibitor z(VAD)-fmk or DMSO and results were evaluated as in (B).
(D and E) Apoptosis (D) and cellular distribution (E) were determined by ﬂow cytometry with propidium iodide-stained cells at the time point of
repair measurements. Sub-G1 fractions were determined and viable cells were divided into G1, S and G2 cell cycle phases (presented in percentages).
Mean values and SEMs from n=6. (F) Expression levels of endogenous IiBa and exogenous IiBa-SR were examined by western blotting.
184 Nucleic Acids Research, 2012,Vol. 40,No. 1without z(VAD)-fmk suggesting that apoptosis-dependent
processes are not involved in TNFa-mediated DSB repair
activation. Because stable overexpression of IiBa-SR was
reported to induce G1-arrest via p21, we also considered
potential cell cycle-dependent effects of IiBa-SR on DSB
repair (11). When analysing propidium iodide stained
cells, we neither detected signiﬁcant changes between
TNFa- and mock treated nor between IiBa-SR expressing
and control samples regarding sub-G1, G1-, S- or
G2-phase fractions (Figure 1D and E).
Role of NF-iB in DSB repair triggered by DNA
damage-inducing chemotherapeutic treatment
DNA damage, especially a DSB, represents one of the
NF-iB-activating stimuli (2). To test whether exposure
to DNA-damaging agents leads to NF-iB-dependent
stimulation of DSB repair, K562(/30) cells were sub-
jected to DSB repair analysis  /+ IiBa-SR expression
and exposed to etoposide, camptothecin or doxorubicin.
Treatment with 50mM etoposide led to a 1.4-fold increase
in DSB repair, which was 2.2-fold down-regulated by
IiBa-SR (P<0.01; Figure 2A). Camptothecin at a con-
centration of 300nM stimulated repair 2.2-fold, which
was 2.7 times down-regulated by IiBa-SR (P<0.01;
Figure 2E). When comparing the effect of 50mM etopo-
side or 300nM camptothecin on DSB repair without
versus with IiBa-SR, we noticed similar fold induc-
tion (etoposide: 1.4- versus 1.5-fold, camptothecin:
2.2- versus 2.3-fold, P>0.05). Applying low concentra-
tions of these drugs still induced DSB repair, namely
1.3- (1mM etoposide) and 1.2-fold (30nM camptothecin),
which was down-regulated 4.8- (etoposide) and 3.7-fold
(camptothecin) by IiBa-SR (P<0.01; Supplementary
Figure S2A and B). However, under these low-dose treat-
ment conditions drug-induced DSB repair was no longer
detectable after IiBa-SR expression (P>0.05). Similarly,
when treating the cells with 0.3mg/ml doxorubicin, DSB
repair was increased (1.7-fold, P=0.0313) in cells without
but no longer in cells with IiBa-SR (Supplementary
Figure S2C). When comparing the fold change of DSB
repair after drug treatment between cells without and
with IiBa-SR, a statistically signiﬁcant difference was
reached for 1mM etoposide (1.3- versus 1.0-fold,
P=0.0195). These data suggested either that IiBa-SR
cannot completely inhibit NF-iB after strong activation
by high topoisomerase inhibitor concentrations or that
NF-iB is only partially required for DSB repair induction
as compared with other DNA damage signalling pathways
triggered by the formation of DNA breaks.
Evaluation of the sub-G1 cellular fraction conﬁrmed
effectiveness of the cytostatics, since cell death was in-
creased (Figure 2B and F). The same data sets excluded
a signiﬁcant inﬂuence of apoptosis on IiBa-SR-
modulated DSB repair, since sub-G1 fractions in control
and IiBa-SR-expressing samples treated with chemo-
therapeutics did not signiﬁcantly change. Cell cycle
analysis revealed that cells exposed to etoposide and
camptothecin accumulated in S-phase (Figure 2C and
G), notably, in a similar manner in IiBa-SR-negative
and -positive samples. Increased phosphorylation of
IiBa 2–24h after etoposide and 0.5–16h after campto-
thecin exposure veriﬁed NF-iB activation by
chemotherapeutics (Figure 2D and H).
The NF-iB subunit p65 stimulates DSB repair
independently of apoptosis
To ascertain the involvement of NF-iB in DSB repair, p65
was expressed in K562(/30) cells (Figure 3I), which were
subjected to I-SceI-triggered DSB repair  /+ IiBa-SR ex-
pression. p65 expression stimulated DSB repair 5.9-fold,
which was down-regulated 3.0-fold by IiBa-SR at 48h
and similarly at the 72h time point with and without
z(VAD)-fmk (P<0.05; Figure 3A, B, E and F; primary
ﬂow cytometric data in Supplementary Figure S3). The
fold change in cells with p65 was reduced by IiBa-SR
expression (48h: 5.9- versus 2.7-fold, P=0.0625; 72h:
4.6- versus 2.8-fold, P=0.0313). Sub-G1 fractions of
cells  /+ IiBa-SR did not differ, strengthening the data
obtained with z(VAD)-fmk showing that DSB repair
changes are independent of differences in apoptosis induc-
tion (Figure 3C and G). p65- or IiBa-SR expression also
had no signiﬁcant inﬂuence on the cell cycle distribution
(Figure 3D and H). To further exclude potential
NF-iB-dependent differences in DNA substrate cutting,
we performed PCR analysis of the chromosomally
integrated D-EGFP gene, which is cleaved by I-SceI. The
results showed that D-EGFP was equally cleaved in cells
with or without concomitant p65 expression, as indicated
by the disappearance of the PCR product and quantitative
real-time PCR data (Supplementary Figure S4A and B).
Equivalent cutting was also observed for mock- and
TNFa treatment.
NF-kB stimulates DSB repair via the HR pathway
To clarify whether NF-iB activation enhances DSB repair
in general or via speciﬁc repair pathways, K562 cells were
transiently transfected with different EGFP-based re-
pair substrates, namely with EJ-EGFP, 50EGFP/HR-
EGFP and HR-EGFP/50EGFP (Figure 4A) together
with I-SceI expression plasmid to assess NHEJ, non-
conservative homologous DSB repair (mostly SSA) and
conservative HR (mostly gene conversion). After p65 ex-
pression, we observed a 1.7- and 1.5-fold stimulation of
NHEJ and SSA, respectively (P<0.05; Figure 4B and C),
indicating minor NF-kB-dependent effects. In contrast,
HR was strongly stimulated by p65 expression
(51.6-fold) and IiBa-SR-reduced p65-stimulated HR
frequencies 3.3 times (P<0.05; Figure 4D). When we
examined DNA exchange without I-SceI, we again moni-
tored a massive p65-mediated HR stimulation with HR-
EGFP/50EGFP (Supplementary Figure S4C). Fluorescent
signals were absent in assays with EJ-EGFP lacking
I-SceI, which is consistent with DSB dependence of
NHEJ-mediated reconstitution of the wtEGFP reading
frame (9). The substrate 50EGFP/HR-EGFP is mostly
repaired by SSA after I-SceI-mediated cleavage, but cross-
over events are still detectable without cleavage.
Expression of p65 did not have a major effect on DNA
exchange with 50EGFP/HR-EGFP (Supplementary
Figure S4C). These data excluded an indirect inﬂuence
Nucleic AcidsResearch, 2012, Vol.40,No. 1 185from I-SceI and conﬁrmed that NF-iB modulates HR.
We noted differences in the degree of HR stimulation by
p65 with intrachromosomal (Figure 3A) as compared with
extrachromosomal (Figure 4D) substrate (6- versus
52-fold), which might be explained by a better accessibility
of extrachromosomal substrates to the end processing and
strand-exchange machinery.
To better understand DSB repair pathway usage within
chromosomally integrated substrate (EGFP/30EGFP
in K562(/30) cells), we expressed I-SceI with or without
p65 for 72h, sorted green ﬂuorescent and white, non-
ﬂuorescent cells ﬂow cytometrically and performed
genomic PCR analysis (Supplementary Figure S5) (9,10).
Ampliﬁcation of a fragment encompassing the EGFP
gene (Supplementary Figure S5A) was followed by restric-
tion analysis using I-SceI and the control enzyme XhoI. In
white cells, I-SceI cleavage failure was the result of
error-prone NHEJ, in green cells the result of conservative
HR (mostly gene conversion) in one of the chromosomally
integrated EGFP/30EGFP copies (Supplementary
Figure S5B). When comparing error-prone NHEJ-
speciﬁc bands (corrected for loading), we quantiﬁed a
1.3-fold increase for cells expressing p65. When comparing
HR-speciﬁc bands (corrected for loading), we quantiﬁed a
1.8-fold increase. When performing genomic PCR analysis
speciﬁc for DSB repair events leading to spacer sequence
C
D
B
E G
H
F
A
0
20
40
60
G1
S
G2
C
e
l
l
u
l
a
r
d
i
s
t
r
i
b
u
t
i
o
n
(
%
)
Control
Control+Cpt
-SR
α
B
κ
I -SR+Cpt
α
B
κ
I
0
20
40
60
G1
S
G2
C
e
l
l
u
l
a
r
d
i
s
t
r
i
b
u
t
i
o
n
(
%
)
Control
Control+Eto
-SR
α
B
κ
I -SR+Eto
α
B
κ
I
0
50
100
150
200
**
**
**
**
**
*
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
20
40
60
S
u
b
-
G
1
 
f
r
a
c
t
i
o
n
(
%
)
tubulin
– +– + – + – +
30 min 2h 16h 24h
camptothecin
Control
Control+Cpt
-SR
α
B
κ
I -SR+Cpt
α
B
κ
I
0
100
200
300 **
**
** **
**
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
20
40
60
80
S
u
b
-
G
1
 
f
r
a
c
t
i
o
n
(
%
)
p-IκBα
– + – + – + – +
tubulin
30 min 2h 16h 24h
etoposide
Control
Control+Eto
-SR
α
B
κ
I -SR+Eto
α
B
κ
I
Control
Control+Eto
-SR
α
B
κ
I -SR+Eto
α
B
κ
I
p-IκBα
Control
Control+Cpt
-SR
α
B
κ
I -SR+Cpt
α
B
κ
I
Figure 2. DSB repair stimulation by chemotherapeutics as a function of NF-iB activity. (A) K562(/30) cells were co-transfected with pCMV-I-SceI
and pcDNA3.0-IiBa-SR/pcDNA3.0 as indicated, cultivated for 24h and then treated with 50mM etoposide (Eto). Cells were further cultivated for
48h, when HR assays were performed. DSB repair frequencies in DMSO-treated controls were deﬁned as 100% (absolute mean value 2 10
 3).
Mean values and SEMs from n=9 (*P<0.05; **P<0.01). (B and C) The percentages of cells with sub-G1 DNA content (B) in G1, S or G2 cell
cycle phases (C) were determined with propidium iodide-stained cells at the time point of the repair measurements. Columns, mean values of n=4;
bars SEMs. (D)I iBa phosphorylation in cells exposed to 50mM etoposide was analysed by western blotting (p- IiBa). (E–H) K562(/30) cells were
co-transfected with pCMV-I-SceI and pcDNA3.0-IiBa-SR/pcDNA3.0, treated with 300nM camptothecin (Cpt) and evaluated as in (A–D). Note
that IiBa degradation interfered with p-IiBa detection 24h after camptothecin addition in (H).
186 Nucleic Acids Research, 2012,Vol. 40,No. 1A
D
C
E
B
H
F
I
G
+
 
z
(
V
A
D
)
-
f
m
k
+
 
z
(
V
A
D
)
-
f
m
k
4
8
h
7
2
h
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
0
2
0
0
4
0
0
6
0
0
8
0
0
*
*
*
*
*
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
*
*
*
*
*
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
1
0
2
0
3
0
4
0
5
0
+
 
z
V
A
D
-
f
m
k
S
u
b
-
G
1
 
f
r
a
c
t
i
o
n
(
%
)
0
2
0
4
0
6
0
8
0
G
1
S
G
2
+
 
z
V
A
D
-
f
m
k
C
e
l
l
u
l
a
r
d
i
s
t
r
i
b
u
t
i
o
n
(
%
)
0
2
0
0
4
0
0
6
0
0
*
*
*
*
*
*
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
1
0
0
2
0
0
3
0
0
4
0
0
5
0
0
*
*
*
*
*
D
S
B
 
r
e
p
a
i
r
f
r
e
q
u
e
n
c
y
 
(
%
)
0
5
1
0
1
5
2
0
2
5
+
 
z
V
A
D
-
f
m
k
S
u
b
-
G
1
 
f
r
a
c
t
i
o
n
(
%
)
0
2
0
4
0
6
0
8
0
G
1
S
G
2
+
 
z
V
A
D
-
f
m
k
C
e
l
l
u
l
a
r
d
i
s
t
r
i
b
u
t
i
o
n
(
%
)
G
A
P
D
H
1
2
h
2
4
h
4
8
h
7
2
h
p
6
5
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
-
S
R
α
B
κ
I
-
S
R
α
B
κ
p
6
5
/
I
C
o
n
t
r
o
l
p
6
5
C
o
n
t
r
o
l
p
6
5
C
o
n
t
r
o
l
p
6
5
C
o
n
t
r
o
l
p
6
5
F
i
g
u
r
e
3
.
E
x
p
r
e
s
s
i
o
n
o
f
t
h
e
N
F
-
i
B
s
u
b
u
n
i
t
p
6
5
e
n
h
a
n
c
e
s
D
S
B
r
e
p
a
i
r
.
(
A
a
n
d
E
)
H
o
m
o
l
o
g
o
u
s
D
S
B
r
e
p
a
i
r
w
a
s
a
n
a
l
y
s
e
d
i
n
K
5
6
2
(

/
3
0
)
c
e
l
l
s
4
8
h
(
A
)
a
n
d
7
2
h
(
E
)
a
f
t
e
r
c
e
l
l
s
h
a
d
b
e
e
n
e
l
e
c
t
r
o
p
o
r
a
t
e
d
w
i
t
h
p
C
M
V
-
I
-
S
c
e
I
,
p
c
D
N
A
3
.
0
-
p
6
5
/
p
c
D
N
A
3
.
0
a
n
d
p
c
D
N
A
3
.
0
-
I
i
B
a
-
S
R
/
p
c
D
N
A
3
.
0
a
s
i
n
d
i
c
a
t
e
d
.
M
e
a
n
v
a
l
u
e
s
f
r
o
m
c
o
n
t
r
o
l
s
w
e
r
e
d
e
ﬁ
n
e
d
a
s
1
0
0
%
(
a
b
s
o
l
u
t
e
m
e
a
n
v
a
l
u
e
s
:
0
.
4
 
1
0
 
3
a
f
t
e
r
4
8
h
,
0
.
9
 
1
0
 
3
a
f
t
e
r
7
2
h
)
;
M
e
a
n
v
a
l
u
e
s
a
n
d
S
E
M
s
f
r
o
m
n
=
6
;
*
P
<
0
.
0
5
.
(
B
a
n
d
F
)
I
n
p
a
r
a
l
l
e
l
e
x
p
e
r
i
m
e
n
t
s
c
e
l
l
s
w
e
r
e
t
r
e
a
t
e
d
w
i
t
h
2
5
m
M
z
(
V
A
D
)
-
f
m
k
.
(
C
,
D
,
G
a
n
d
H
)
A
p
o
p
t
o
s
i
s
(
C
a
n
d
G
)
a
n
d
c
e
l
l
c
y
c
l
e
d
i
s
t
r
i
b
u
t
i
o
n
(
D
a
n
d
H
)
w
e
r
e
a
n
a
l
y
s
e
d
u
n
d
e
r
t
h
e
s
a
m
e
c
o
n
d
i
t
i
o
n
s
a
s
i
n
(
A
)
a
n
d
(
E
)
.
M
e
a
n
v
a
l
u
e
s
a
n
d
S
E
M
s
f
r
o
m
n
=
4
.
(
I
)
W
e
s
t
e
r
n
b
l
o
t
a
n
a
l
y
s
i
s
v
e
r
i
f
y
i
n
g
p
6
5
e
x
p
r
e
s
s
i
o
n
.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 187deletion such as via SSA (9,10), we were unable to detect
the corresponding PCR products both in control and p65
expressing cells (data not shown). To examine chromo-
somal DSB repair in another cell type, we correspond-
ingly analysed WTK1(HR/30) cells (Supplementary
Figure S5C), which carry substrate HR-EGFP/30EGFP
(12). PCR fragments speciﬁc for error-prone NHEJ were
hardly detectable, and quantiﬁcation of band intensities
did not indicate an increase for cells expressing p65.
However, HR-speciﬁc bands (corrected for loading)
revealed a 3.9-fold increase upon p65 expression. These
data support the notion that NF-iB promotes the HR
pathway in the extra- and intrachromosomal context.
To prove cell type-independency, we applied the EGFP-
based repair assay on U87MG glioblastoma cell deriva-
tives, stably expressing IiBa-SR (U87MG-SR). In
accordance with the data obtained in K562 cells, HR
was several-fold down-regulated in U87MG-SR
(Supplementary Figure S6A and B). In the presence of
the caspase inhibitor z(VAD)-fmk this HR frequency
change became even more pronounced [without z(VAD)-
fmk: 2.6-fold; with z(VAD)-fmk: 6.8-fold; P values<0.01].
Moreover, when we analysed HR in response to
TNFa-treatment, we measured a 9.3-fold (P=0.0117)
HR increase which was abrogated in the presence of
IiBa-SR (P>0.05) (Supplementary Figure S6C).
These data indicated that NF-iB is necessary also for
TNFa-mediated activation of the HR pathway.
NF-iB-dependent DSB repair induction is not mediated
by Bcl2-family members
Proteins from the Bcl2-family represent classical NF-iB
target genes that are well-known anti- and pro-apoptotic
factors and have been implicated in HR (13–15).
Consequently, we investigated whether these molecules
are responsible for NF-iB-dependent DSB repair stimu-
lation. Bcl2, Bcl-xL or BAX were silenced in K562(/30)
cells via transfection with speciﬁc shRNA plasmids.
Reduction of Bcl2 levels by 57–70% (Figure 5C) and
BAX levels by 96% (Figure 5I) did not signiﬁcantly
change p65-stimulated DSB repair without or with
caspase inhibition (Figure 5A, B, G and H). Differently,
Bcl-xL depletion by 72% (Figure 5F) led to a 1.9-fold
(P=0.0005) down-regulation of p65-mediated DSB
repair, but this effect was lost when apoptosis was blocked
by z(VAD)-fmk (Figure 5D and E). Interestingly, when
evaluating the effect of Bcl2, Bcl-xL and BAX on DSB
repair without p65 expression, we noticed a 1.7-fold
increase (P=0.0313) of repair frequencies after Bcl-xL
silencing, however, only after z(VAD)-fmk treatment.
Taken together, we observed that contrary to the differ-
ential Bcl-xL effects, Bcl2 and BAX knockdown did not
B D C NHEJ HR SSA
EJ-EGFP
Microhomology mediated
non-homologous end joining,
NHEJ
EJ-EGFP
5´EGFP/HR-EGFP
Non-conservative homologous repair
(Single-strand annealing),
SSA
HR-EGFP 5´EGFP
HR-EGFP/5´EGFP
Conservative
homologous recombination, 
HR
5´EGFP HR-EGFP
A
Figure 4. NF-iB-dependent DSB repair stimulation affects mostly HR. (A) Substrate design for the assessment of different DSB repair pathways. In
plasmid substrate EJ-EGFP, the I-SceI site (triangle) is ﬂanked by 5bp microhomologies for detection of microhomology-mediated NHEJ. Substrate
HR-EGFP/50EGFP enables the analysis of conservative HR (mostly gene conversion) and 50EGFP/HR-EGFP assessment of non-conservative
homologous repair (mostly SSA after I-SceI-mediated cleavage). Mutated EGFP genes: grey boxes; spacer sequence: white box; deleted EGFP
sequence: cross; (B–D) K562 cells were co-transfected with pCMV-I-SceI plus pcDNA3.0-p65/pcDNA3.0 and pcDNA3.0-IiBa-SR/pcDNA3.0
plus repair substrates to assess NHEJ (B), SSA (C) or HR (D). DSB repair was measured 48h after transfection. Mean values and SEMs from
n=6 (*P<0.05), controls were deﬁned as 100% each (absolute mean value for NHEJ: 2.7 10
-3, SSA: 2.7 10
 2, HR: 0.4 10
 3).
188 Nucleic Acids Research, 2012,Vol. 40,No. 1inﬂuence DSB repair. Consistently, immunoblotting con-
ﬁrmed Bcl-xL (2-fold up-regulation) but not Bcl2 or BAX
as NF-kB-induced target gene.
NF-iB-dependent enhancement of DSB repair requires
up-regulated HR proteins
Since we found HR to be the DSB repair pathway
stimulated by p65, we examined the NF-iB target gene
products and HR proteins ATM and BRCA2 (16,17).
HR analysis with transiently transfected HR-EGFP/
50EGFP was performed in HeLa derivatives, in which
ATM or BRCA2 were stably silenced. In the control
HeLa line, we observed on average 2.9-fold enhancement
of HR by p65 (P=0.0022). Both in the ATM and
BRCA2 knockdown lines, this effect was completely abol-
ished (Figure 6A and C) implying that ATM and BRCA2
are downstream effectors of p65 in DSB repair enhance-
ment. ATM and BRCA2 protein levels were 11- and
1.8-fold up-regulated upon p65 expression, which was
lost in the corresponding knockdown cells (Figure 6B
and D). Interestingly, we also noticed a 7.3-fold BRCA1
accumulation, whereas Mre11 levels remained unaffected
(Figure 6F and H). In BRCA1 knockdown cells HR
stimulation by p65 was again abrogated (Figure 6E). In
Mre11 knockdown cells, HR was reduced both in cells
with and without p65 expression so that p65-dependent
HR enhancement (6.4-fold, P=0.0043) was still observ-
able (Figure 6G).
Since a BRCA1–p65 interaction had been reported (7),
we tested the involvement of BRCA1 in p65-regulated
DSB repair also in another cellular system. In K562(/
30) BRCA1 protein was up-regulated 2.4-fold by p65
(Figure 6J). Transient BRCA1 silencing by 51–74%
reduced p65-dependent DSB repair stimulation 2.5-fold
(P=0.0005 for difference between fold induction)
(Figure 6I and J). Because BRCA1 and CtIP form a
complex which is important for ssDNA-end formation
as a prerequisite for HR (18,19), we performed DSB
repair analysis in K562(/30) with transient CtIP
knockdown. Interestingly, silencing CtIP by 61–77%
reduced p65-dependent DSB repair stimulation 1.8-fold
(P=0.0005 for difference between fold induction)
(Figure 6K and L). Equivalent results were obtained with
z(VAD)-fmk (data not shown). Finally, we also examined
the effect of p65 expression on HR in lymphoblastoid cell
lines derived from patients with mutations in BRCA2 or
BRCA1 (20). As displayed in Supplementary Figure S7,
expression of p65 stimulated HR 2.4-fold (P<0.0001) in
control lymphoblastoid cells. In accordance with the
BRCA2/BRCA1-mutated status, HR was severely reduced
in both patient cell lines, and p65 expression had no stimu-
latory effect on HR.
Because previous publications revealed competition
between HR and NHEJ (4,21–23), we also tested the
NF-iB target gene and NHEJ component Ku70 (24).
Here, we noticed a 3.1-fold increase of Ku70 levels after
p65 expression in K562(/30) cells and a 3.6-fold decrease
following transient knockdown (Figure 6N). However, we
did not observe a reduction of p65-dependent DSB repair
stimulation upon Ku70 knockdown arguing against Ku70
involvement (Figure 6M).
Activation of NF-iB stimulates interactions with
CtIP–BRCA1 complexes and accelerates the
formation of RPA foci formation
To test whether BRCA1 interacts with NF-iB and
whether this interaction is modulated by NF-iB activation
in K562(/30), DSBs were induced by I-SceI expression
followed by treatment with TNFa and subsequent
immunoprecipitation with antibodies directed against
BRCA1 and p65. Pull down of BRCA1 resulted in the
co-precipitation of p65 and CtIP, pull down of p65 led
to co-precipitation of CtIP, but not BRCA1
(Figure 6O), arguing for a direct and probably more
stable contact of p65 with CtIP. In both cases, more
CtIP protein was co-precipitated after TNF-a exposure,
even though the total amount of p65 protein remained the
same. For BRCA1, we had observed a p65-dependent
increase of the protein level in different cell types
(Figure 6F and J). To test whether NF-iB inﬂuences
BRCA1 stability, cells were pre-treated with cyclo-
heximide to block translation followed by TNF-a
exposure. After TNF-a treatment, a 2-fold BRCA1
increase was observed (Figure 6O and P). Cycloheximide
exposure resulted in complete disappearance of BRCA1
in untreated cells, while TNFa treatment allowed accumu-
lation of BRCA1 even in cycloheximide-treated cells,
suggesting that NF-iB activation stabilizes BRCA1
(Figure 6P). For comparison, the protein levels of CtIP
or Ku70 were only marginally affected by TNFa.
CtIP is known to promote DSB resection to generate
ssDNA ends for HR (18) and to collaborate with BRCA1
in this process (25,26). Therefore, we investigated a poten-
tial role of NF-kB in the generation of resected ssDNA
after introduction of DSBs into the cellular genome. Thus,
we exposed SaOS cells, which also showed HR stimulation
in response to NF-iB activation (data not shown), to
increasing concentrations of the radiomimetic drug bleo-
mycin alone or in combination with TNFa and monitored
53BP1, RPA and Rad51 foci assembly as markers of DSB,
ssDNA and Rad51 ﬁlament formation, respectively. As
expected, nuclear 53BP1 foci continuously accumulated
in response to bleomycin treatment over a time period
of 24h (Figure 7A and D–F). After combined bleomycin-
and TNFa treatment, we counted similar or even higher
numbers of 53BP1 foci per cell within the ﬁrst 2–6h of
treatment. At later time points (6–24h), we noticed a
decrease in 53BP1 foci numbers rather than a further
increase, which is consistent with an enhanced homolo-
gous DSB repair in response to NF-iB activation. When
analysing RPA, we observed accelerated foci formation in
bleomycin and TNFa co-treated samples compared to
bleomycin-treated cells as it became evident from the
RPA foci number increase 6h after drug exposure for dif-
ferent bleomycin concentrations (Figure 7B and G–I).
Twenty-four hours after drug exposure the increase in
RPA foci formation in TNFa co-treated samples dis-
appeared, most likely due to continuation of DNA
repair. Rad51 foci numbers were higher in TNFa
Nucleic AcidsResearch, 2012, Vol.40,No. 1 189co-treated samples 6–24h after drug exposure (Figure 7C,
J–L). Following transfection of cells with p65 expression
or control plasmid and subsequent bleomycin treatment,
53BP1, RPA and Rad51 foci number changes were com-
parable to the ones observed in cells with or without
TNFa co-treatment (Figure 7M–O). These data suggested
that NF-iB activation stimulates DSB resection, which is
mediated by CtIP–BRCA1 complexes, i.e. interaction
partners of p65, and ﬁlament formation of Rad51, which
binds the NF-iB target gene product BRCA2.
DISCUSSION
A speciﬁc role of NF-iB in DSB repair
Activation of NF-iB by the DSB-induced kinase ATM
provides an anti-apoptotic signal in balance with
apoptosis induction by p53 (2). Despite the identiﬁcation
of NF-iB target genes, which encode DSB repair factors
(16,17,24), very little was known about a functional role of
NF-iB in DSB repair. We show that NF-iB strongly
stimulates the removal of DSBs by enhancement of HR.
Intriguingly, this again balances an antagonistic action of
p53 in HR (27). The effectiveness of TNFa exposure, p65
expression and IiBa-SR-mediated suppression of NF-kB
activation implies an involvement of the protoypical NF-
iB heterodimer p50/p65, which is quickly activated fol-
lowing IiBa phosphorylation and degradation, thereby
assuring a timely response for the removal of the most
detrimental DNA lesion, namely a DSB.
Recent data identiﬁed the DNA single-strand break
sensor PARP1 as critical NF-iB regulator (3). PARP1
senses stalled replication forks and promotes recombina-
tive replication restart (28). NF-iB is most probably also
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Figure 5. Role of Bcl2-family proteins in NF-iB-mediated DSB repair regulation. (A, D and G) K562(/30) cells were co-transfected with
pCMV-I-SceI, pcDNA3.0-p65 or empty vector plus a mixture of two different shRNA expression plasmids directed against Bcl2, Bcl-xL or BAX
or empty vector. DSB repair frequencies were measured 72h post-transfection; mean values of controls were taken as 100% each (absolute mean
value 1 10
 3). Columns, mean values of n=6–12; bars, SEM; *P<0.05; ***P<0.001. (B, E and H) Cells were treated with 25mM z(VAD)-fmk
and homologous DSB repair was assayed as in (A, D and G). (C, F and I) Immunoblot analysis showing Bcl2, Bcl-xL and BAX knockdown.
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Nucleic AcidsResearch, 2012, Vol.40,No. 1 191activated by single-stranded breaks, because UV-induced
NF-iB activation is abolished in XPC/D deﬁcient primary
ﬁbroblasts, which are blocked before lesion excision
creates ssDNA breaks (29). Experiments with hydroxy-
urea and aphidicolin identiﬁed also DNA replication
arrest as NF-iB inducer (30). In our study, HR stimula-
tion by NF-iB was not dependent on I-SceI-induced
DSBs. To obtain ﬁrst insight into the impact of NF-iB
on replication stress sensitivity, we assessed cell viability
following treatment of K562(/30) cells with the PARP
inhibitor IQD, and noticed an  50% increase of the
IC50 value upon expression of p65. Thus, NF-iB
triggers HR that removes any breaks arising spontaneously
or in response to genotoxic stress.
Involvement of NF-iB downstream signalling
NF-iB is known best for its role in transcriptionally
regulating a myriad of target genes regulating diverse bio-
logical processes (http://people.bu.edu/gilmore/nf-kb/).
To avoid functional interactions with the target gene
product p53 (31), which is also modulated by IiBa-SR
(11), we chose p53-negative (K562, SaOS) or -depleted
(HeLa) cells in this work. Nevertheless HR stimulation
by NF-iB was not limited to p53-mutated cells, as it
was also detected in wtp53-positive U87MG glioblastoma
cells. The apoptosis-regulatory target genes Bcl-2, Bcl-xL
and BAX were proposed to act downstream of NF-iBi n
DSB repair regulation, since the corresponding gene prod-
ucts had been implicated in HR (13–15). We did not
observe an inﬂuence of Bcl-2 or BAX on NF-iB-
mediated DSB repair. Regarding Bcl-xL, a partial contri-
bution was seen but lost in cells treated with z(VAD)-fmk,
suggesting that apoptosis suppression by Bcl-xL ameliorates
NF-iB-mediated DSB repair stimulation. Interestingly,
when NF-iB was not activated, our knockdown experi-
ments revealed a moderate antagonistic effect of Bcl-xL.
Our results may reconcile earlier discrepancies on the in-
volvement of Bcl-xL in HR. Thus, HR stimulation by
Bcl-xL observed by Kronenberg and co-workers (14)
might have been inﬂuenced by an increased propensity
of human lymphoblastoid TK6 cells to undergo apoptosis
due to wtp53 expression in combination with active
NF-iB in these cells.
The DNA-PK subunits Ku70 and Ku80 were shown to
become up-regulated by NF-iB (24). In agreement with
the fact that DNA-PK initiates canonical NHEJ processes
rather than HR, we did not observe any contribution of
Ku70 to NF-iB-mediated DSB repair. NF-iB was also
proposed to transcriptionally induce polymerase b,
which stimulates HR and causes genetic instabilities in
tumour cells upon overexpression (32,33). Pathogenesis
of Werner syndrome was also suggested to involve
NF-iB signalling. Werner syndrome is caused by muta-
tions in WRN, which has a role in the resolution step of
homology-directed repair (34). We neither saw an effect of
polymerase b nor WRN knockdown on NF-iB-mediated
DSB repair (data not shown). To the contrary, when we
analysed the involvement of the downstream gene
products BRCA2 and ATM (16,17), we completely lost
NF-iB-dependent HR enhancement. BRCA2 facilitates
Rad51 ﬁlament assembly in HR (35) and ATM is the
key DSB-signalling kinase that directly phosphorylates
proteins, which are critically involved in HR. Moreover,
it transmits the DNA damage signal to BRCA2 via Chk2
and to Rad51 via c-Abl (36,37). Knockdown of the
initial HR component Mre11 compromised HR with or
without NF-iB activation. These observations supported
the notion that BRCA2- and ATM induction by NF-iB
stimulate HR, whereas Mre11 complexes are equally ne-
cessary to exert basal and NF-iB-dependent HR
processes.
Identiﬁcation of a direct link between NF-iB and the
DNA end processing CtIP–BRCA1 complex
Our data further provide evidence for a crucial role of
CtIP–BRCA1 complexes in NF-iB-mediated HR. We hy-
pothesize that direct interactions between p65 and CtIP–
BRCA1 complexes stabilize BRCA1 protein, providing a
novel mechanism for NF-iB-mediated downstream
signalling in addition to its role as transcription factor.
Indeed, protein stabilization represents a major mechan-
ism for BRCA1 regulation (38). We further propose that
these interactions have functional consequences, namely
accelerated processing of DSBs. CtIP exonucleolytically
generates extensive 30 ssDNA overhangs at DSBs
(18,39). CtIP does not inﬂuence canonical NHEJ but pro-
motes HR, SSA and error-prone NHEJ, which may
explain the modest stimulatory effects of NF-iBo n
microhomology-mediated NHEJ and SSA that we ob-
served in this study (4). Recruitment of CtIP by BRCA1
is necessary for HR but not error-prone NHEJ shifting the
balance of DSB repair to HR (26). Notably,
Souto-Carneiro et al. (40) found that NF-iB is involved in
controlling the exonucleolytic activity on the coding ends
during V(D)J recombination, whereby the authors ex-
cluded an inﬂuence of NF-iB on terminal deoxynucleo-
tide transferase, Artemis and DNA-PKcs.
Altogether, NF-iB utilizes multiple mechanisms to
activate HR, as is outlined in the model in Figure 7P: In
a rapid step, IkBa released NF-iB dimers associate with
and stimulate the activity of CtIP–BRCA1 complexes to
trigger DNA end processing, the initial step of homolo-
gous DSB repair. In a subsequent process, NF-iB tran-
scriptionally up-regulates BRCA2 and ATM. BRCA2
channels homologous DSB repair into the HR pathway
(35). Increased ATM kinase levels assure fully efﬁcient
HR through signalling to Mre11, Rad50, Nibrin, CtIP,
BRCA2 and BRCA1 (36,37) and contributes to the mani-
festation of the pathway choice, since phosphorylation of
BRCA1 by the ATM downstream kinase Chk2 promotes
HR versus error-prone NHEJ (41). Our model does not
take into account that many of the downstream compo-
nents have also been described to act upstream of NF-iB:
BRCA1 was shown to augment transcription by NF-iB
(7) and ATM phosphorylates IKKg in the nucleus (1,2).
Activation of multiple molecular targets by NF-iB and
signal ampliﬁcation by feed forward loops might ensure
strong and rapid activation of HR.
192 Nucleic Acids Research, 2012,Vol. 40,No. 1Implications
In high-risk MDS and AML ATM becomes activated
during the transformation process resulting in constitutive
NF-iB activation (42). NF-iB is also activated in the
mammary progenitor population before formation of
mammary luminal-type epithelial neoplasias (43). Of
note, recombination-mediated bypass of stalled
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Figure 7. Inﬂuence of TNFa on 53BP1, RPA and Rad51 foci assembly. SaOS cells were exposed to bleomycin (7.5–100mU) alone or in combination
with TNFa 10ng/ml (A–L). In Figure 7M–O cells were transfected with pcDNA3.0 or pcDNA3.0-p65, cultivated for another 24h and then treated
with bleomycin. (A–C) At the indicated incubation times after treatment with 15mU bleomycin, cells were processed for immunolabeling of 53BP1
(A), RPA (B), or Rad51 (C) to visualize foci assembly. (D–O) Immunolabeled foci from two independent experiments were scored by automated
quantiﬁcation in 50 nuclei from two separate slides for each time point. Bleomycin concentrations: 7.5mU (D, G and J), 15mU (E, H and K), 30–
100mU (F, I, L and M–O). Maximum scores were set to 100%. (P) Model of NF-iB-dependent DSB repair regulation.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 193replication forks is necessary for replication restart and
cellular survival during oncogene-induced replication
stress in preneoplastic lesions (28). Here, we observed a
requirement of NF-kB for induction of the DSB repair
pathway HR in particular (Figure 4; Supplementary
Figures S4C and S5). HR enhancement in response to
constitutive NF-iB activation will permit accelerated pro-
liferation of these preneoplastic cells. Thus, even though
reduced HR activities are known to increase cancer prone-
ness (35), uncontrolled excess recombination, in our study
as a result of NF-iB activation, equally causes genetic
instabilities and promotes carcinogenesis (33). In this
context, it is of interest that TNFa, for which we demon-
strated NF-iB-dependent HR induction, was shown to
induce chromosomal instabilities in apoptosis-deﬁcient
leukaemia cells (44). TNFa may additionally induce hom-
ologous DSB repair pathways independently of NF-iB
such as via JNK signalling (45).
Accumulating evidence indicates that NF-iB mediates
resistance to anti-cancer therapies involving genotoxic
treatment (46,47). In the light of our ﬁndings indicating
that NF-kB may mediate DSB repair induction in
response to topoisomerase inhibition at least partially or
after low-dose treatment, it is of interest that CtIP and
BRCA1 collaborate in the elimination of covalently
bound polypeptides from DSBs after camptothecin- or
etoposide treatment (25). NF-iB-mediated signalling to
CtIP-BRCA1 may therefore underlie resistance to
topoisomerase-trapping drugs and explain enhanced
cytotoxicities when NF-iB inhibitors are administered in
conjunction with cytostatic drugs. It will be of high
interest to analyse whether accelerated removal of complex
DSBs contributes to NF-iB-mediated adaptive resistance
to radiotherapy (46). Our data further suggest that the
NF-iB status may be an important parameter regarding
the design of individual conditioning regimens during
bone marrow transplantation therapies. In particular, im-
munodeﬁciency patients with mutations in the NF-iB
pathway are predicted to show increased sensitivities to
genotoxic therapies (48). Altogether, our ﬁndings on the
function of NF-iB activation in regulating DSB repair
may impact on the design of individualized treatment
protocols for immunodeﬁciency and cancer patients.
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